Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate.

Chemoprevention, especially through the use of naturally occurring phytochemicals capable of impeding the process of one or more steps of carcinogenesis process, is a promising approach for cancer management. Despite promising results in preclinical settings, its applicability to humans has met with limited success largely due to inefficient systemic delivery and bioavailability of promising chemopreventive agents. Here, we introduce the concept of nanochemoprevention, which uses nanotechnology for enhancing the outcome of chemoprevention. We encapsulated green tea polyphenol epigallocatechin-3-gallate (EGCG) in polylactic acid-polyethylene glycol nanoparticles and observed that encapsulated EGCG retains its biological effectiveness with over 10-fold dose advantage for exerting its proapoptotic and angiogenesis inhibitory effects, critically important determinants of chemopreventive effects of EGCG in both in vitro and in vivo systems. Thus, this study could serve as a basis for the use of nanoparticle-mediated delivery to enhance bioavailability and limit any unwanted toxicity of chemopreventive agents, such as EGCG.

[1]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[2]  H. Mukhtar,et al.  Lupeol Inhibits Growth of Highly Aggressive Human Metastatic Melanoma Cells In vitro and In vivo by Inducing Apoptosis , 2008, Clinical Cancer Research.

[3]  R. Rosengren,et al.  Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. , 2006, Life sciences.

[4]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[5]  F. B. Davis,et al.  The Proangiogenic Action of Thyroid Hormone Analogue GC-1 Is Initiated at an Integrin , 2005, Journal of cardiovascular pharmacology.

[6]  S. Nie,et al.  Nanotechnology applications in cancer. , 2007, Annual review of biomedical engineering.

[7]  Mohammad Saleem,et al.  Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. , 2006, Cancer research.

[8]  Chunxin Zhang,et al.  Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[9]  D. Daliani Development of angiogenesis inhibition as therapy for prostate cancer. , 2000, Oncology.

[10]  V. Adhami,et al.  Prevention of prostate cancer through custom tailoring of chemopreventive regimen. , 2008, Chemico-biological interactions.

[11]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[12]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[13]  Yihai Cao,et al.  Angiogenesis inhibited by drinking tea , 1999, Nature.

[14]  V. Adhami,et al.  Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo , 2007, Clinical Cancer Research.

[15]  V. Adhami,et al.  Tea Beverage in Chemoprevention of Prostate Cancer: A Mini-Review , 2003, Nutrition and cancer.

[16]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[17]  V. Adhami,et al.  Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis , 2008, Oncogene.

[18]  Nobuhiro Nishiyama,et al.  Nanomedicine: nanocarriers shape up for long life. , 2007, Nature nanotechnology.

[19]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[20]  S. Wise Nanocarriers as an emerging platform for cancer therapy , 2007 .